Invectys Overview

  • Year Founded
  • 2010

Year Founded

  • Status
  • Private

  • Employees
  • 19

Employees

  • Latest Deal Type
  • Later Stage VC

  • Latest Deal Amount
  • $4M

  • Investors
  • 9

Invectys General Information

Description

Operator of a biopharmaceutical company intended to offer an immunotherapy approach to treat cancer. The company focuses on mobilizing and restoring the anti-tumor capacity of the immune system of cancer patients by targeting a broad-ranging cancer antigen, enabling healthcare practitioners to target telomerase in the cell and improve patients' health.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 2415 West Alabama
  • Suite 220
  • Houston, TX 77098
  • United States
+1 (585)
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Biotechnology
Corporate Office
  • 2415 West Alabama
  • Suite 220
  • Houston, TX 77098
  • United States
+1 (585)

Invectys Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Invectys Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
12. Later Stage VC 10-Oct-2024 $4M Completed Clinical Trials - Phase 2
11. Accelerator/Incubator 26-May-2023 Completed Clinical Trials - Phase 2
10. Later Stage VC (Series B) Completed Clinical Trials - Phase 2
9. Grant 20-May-2020 Completed Clinical Trials - Phase 2
8. Later Stage VC (Series A) 29-Oct-2018 Completed Clinical Trials - Phase 2
7. Later Stage VC 12-Jul-2017 Completed Clinical Trials - Phase 2
6. Later Stage VC 21-Jan-2016 Completed Clinical Trials - Phase 2
5. Grant 21-Jan-2016 Completed Clinical Trials - Phase 2
4. Later Stage VC 30-Mar-2015 $1.81M $14.3M Completed Clinical Trials - Phase 2
3. Early Stage VC 30-Jul-2014 $7.88M $12.4M Completed Startup
To view Invectys’s complete valuation and funding history, request access »

Invectys Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A
Ordinary
Ordinary
Ordinary
Ordinary 10,667 $0.344934 $107.79 $107.79 1x $107.79 3.22%
Ordinary 23,333 $0.344934 $68.99 $68.99 1x $68.99 7.04%
To view Invectys’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Invectys Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Operator of a biopharmaceutical company intended to offer an immunotherapy approach to treat cancer. The company focuses
Drug Discovery
Houston, TX
19 As of 2025

Houston, TX
 

Emeryville, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Invectys Competitors (102)

One of Invectys’s 102 competitors is Iterion Therapeutics, a Venture Capital-Backed company based in Houston, TX.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Iterion Therapeutics Venture Capital-Backed Houston, TX
Nexoplex bio Formerly VC-backed Emeryville, CA
EnGeneIC Formerly VC-backed Sydney, Australia
Renova Therapeutics Venture Capital-Backed Carlsbad, CA
Immune-Onc Therapeutics Venture Capital-Backed Palo Alto, CA
You’re viewing 5 of 102 competitors. Get the full list »

Invectys Patents

Invectys Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2023402360-A1 Humanized anti-hla-g chimeric antigen receptors and uses thereof Pending 28-Nov-2022
EP-4626473-A1 Humanized anti-hla-g chimeric antigen receptors and uses thereof Inactive 28-Nov-2022
WO-2024118469-A1 Humanized anti-hla-g chimeric antigen receptors and uses thereof Inactive 28-Nov-2022
WO-2022079308-A1 Chimeric constructs useful in vaccination and cancer therapy Inactive 16-Oct-2020
JP-7627687-B2 Single domain antibodies against lilrb2 Active 20-Sep-2019 C07K16/2803
To view Invectys’s complete patent history, request access »

Invectys Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Invectys Investors (9)

Investor Name Investor Type Holding Investor Since Participating Rounds
Matwin Accelerator/Incubator
Cancer Prevention and Research Institute of Texas Government
Golda Darty Partners Family Office Minority
Johnson Financial Group Family Office Minority
Very Corporation Minority
You’re viewing 5 of 9 investors. Get the full list »

Invectys FAQs

  • When was Invectys founded?

    Invectys was founded in 2010.

  • Where is Invectys headquartered?

    Invectys is headquartered in Houston, TX.

  • What is the size of Invectys?

    Invectys has 19 total employees.

  • What industry is Invectys in?

    Invectys’s primary industry is Drug Discovery.

  • Is Invectys a private or public company?

    Invectys is a Private company.

  • What is Invectys’s current revenue?

    The current revenue for Invectys is .

  • How much funding has Invectys raised over time?

    Invectys has raised $83M.

  • Who are Invectys’s investors?

    Matwin, Cancer Prevention and Research Institute of Texas, Golda Darty Partners, Johnson Financial Group, and Very are 5 of 9 investors who have invested in Invectys.

  • Who are Invectys’s competitors?

    Iterion Therapeutics, Nexoplex bio, EnGeneIC, Renova Therapeutics, and Immune-Onc Therapeutics are some of the 102 competitors of Invectys.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process